2019, Number 5
PDF size: 129.68 Kb.
ABSTRACTBackground: Pre-eclampsia (PE) is an important cause of morbidity and mortality in our country.
Objective: Evaluate if the administration of acetylsalicylic acid (ASA) at a low dose reduces its presence.
Methods: Comparative, cohort study. Pregnant women with risk factors for PE: Primigravidae, PE antecedent and twin pregnancy were included. Primigravidae and multigested with previous vascular pathology weren’t included. Group 1: 150, 11 excluded, 80 mg ASA from week 20 at the end of pregnancy. Group II: 150, without ASA. The presence of PE or gestational hypertension (HG) was monitored. General data and clinical controls were taken. Chi square and relative risk (RR) were calculated.
Results: Group I: n = 139, 26 ± 5.6 years, 9% PE. Group II: n = 150, 25.5 ± 5.6 years, PE 20% (p = 0.01), RR 0.47 (95% CI 0.19 - 0.87) (p = 0.01), attributable risk -0.11 equivalent to an absolute reduction of 11% for PE in group I.
Conclusions: Pregnant women with risk factor for PE who received ASA diminished the risk of developing PE in 50%.
Panagodage S, Yong HE, Da Silva F, Borg AJ, Kalionis B, Brennecke SP, et al. Low-Dose Acetylsalicylic Acid Treatment Modulates the Production of Cytokines and Improves Trophoblast Function in an in Vitro Model of Early-Onset Preeclampsia. Am J Pathol. 2016;186(12): 3217-3224. DOI: 10.1016/j.ajpath.2016.08.010.
American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5): 1122-31. DOI: 10.1097/01.AOG.0000437382.03963. 88.
Centro Nacional de Excelencia Tecnológica en Salud. Guía de Práctica Clínica (GPC) para la Detección y Diagnóstico de Enfermedades Hipertensivas del Embarazo. México: Secretaría de Salud; 2010. Disponible en: http://www. cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/ 058_GPC_Enf.HipertdelEmb/HIPERTENSION_EMBARAZ ADAS_EVR_CENETEC.pdf